高血圧治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Hypertension Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Key buying criteria

PART 05: Cardiovascular drugs market
• Global pharmaceuticals market
• Global cardiovascular drugs market

PART 06: Overview: Hypertension
• Systemic hypertension
• PAH

PART 07: Epidemiology and economic burden
• Economic burden

PART 08: Pipeline portfolio

PART 09: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 10: Market segmentation by type
• Global systemic hypertension drugs market
• Global PAH drugs market

PART 11: Market segmentation by drug class
• Systemic hypertension
• PAH

PART 12: Geographical segmentation
• Global hypertension drugs market by geographical segmentation 2015-2020
• Hypertension drugs market in Americas
• Hypertension drugs market in EMEA
• Hypertension drugs market in APAC

PART 13: Market drivers
• Growing older population
• Rise in sedentary lifestyle
• High prevalence of chronic conditions
• Patient assistance programs

PART 14: Impact of drivers

PART 15: Market challenges
• Patent expiries of major drugs
• Adverse effects
• Poor patient compliance
• Availability of alternative therapies

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Increase in awareness
• Increased focus on combination therapies
• Intense competition among vendors
• Strategic alliances

PART 18: Vendor landscape
• Competitive scenario
• Market share 2015
• Novartis
• Daiichi Sankyo
• Actelion Pharmaceuticals
• Boehringer Ingelheim
• Sanofi
• AstraZeneca
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for drugs that treat hypertension
Exhibit 03: Patent expiries of major cardiovascular drugs
Exhibit 04: Global cardiovascular drugs market by generic and branded drugs sales 2015
Exhibit 05: Top 10 companies in global cardiovascular drugs market 2014
Exhibit 06: Pathophysiology of hypertension
Exhibit 07: Treatment algorithm for hypertension
Exhibit 08: Prevalence of PAH by cause
Exhibit 09: Projected prevalence of CVDs in US 2010-2030 (% of population)
Exhibit 10: Prevalence of hypertension in US population 2010-2030 (% of population)
Exhibit 11: Projected direct and indirect burden of hypertension in US 2010-2030 ($ billions)
Exhibit 12: Projected mortality trend for CVDs globally 2015 and 2030
Exhibit 13: Pipeline portfolio: Global systemic hypertension drugs
Exhibit 14: Pipeline portfolio: Global PAH drugs
Exhibit 15: Market share of global hypertension drugs in global pharmaceutical market 2015
Exhibit 16: Global hypertension drugs market 2015-2020 ($ billions)
Exhibit 17: Five forces analysis
Exhibit 18: Global hypertension drugs market segmentation by type 2015
Exhibit 19: Global systemic hypertension drugs market 2015-2020 ($ billions)
Exhibit 20: Global PAH drugs market 2015-2020 ($ billions)
Exhibit 21: Segmentation of global hypertension drugs market by drug class
Exhibit 22: Global systemic hypertension drugs market share by drug class 2015
Exhibit 23: Global PAH drugs market share by drug class 2015
Exhibit 24: Segmentation of global hypertension drugs market based on geography 2015
Exhibit 25: Hypertension drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 26: Percentage share of hypertension drugs market by geography 2015-2020
Exhibit 27: Hypertension drugs market in Americas 2015-2020 ($ billions)
Exhibit 28: Hypertension drugs market in EMEA 2015-2020 ($ billions)
Exhibit 29: Hypertension drugs market in APAC 2015-2020 ($ billions)
Exhibit 30: Global hypertension drugs market: YoY growth rate and revenue based on geography 2015-2020
Exhibit 31: Population aged 60 years and over: World, developed, and developing regions ($ millions)
Exhibit 32: Impact of drivers
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Sales of major drugs in global hypertension drugs market 2014 ($ billions)
Exhibit 35: Novartis: YoY growth rate and revenue of Diovan 2012-2015 ($ billions)
Exhibit 36: Novartis: YoY growth rate and revenue of Exforge 2012-2015 ($ billions)
Exhibit 37: Novartis: Key takeaways
Exhibit 38: Daiichi Sankyo: YoY growth rate and revenue of Olmetec in Japan 2012-2014 ($ millions)
Exhibit 39: Daiichi Sankyo: YoY growth rate and revenue of Olmetec/Olmetec Plus in Europe 2012-2014 ($ millions)
Exhibit 40: Daiichi Sankyo: YoY growth rate and revenue of Rezaltas in Japan 2012-2014 ($ millions)
Exhibit 41: Daiichi Sankyo: YoY growth rate and revenue of Artist in Japan 2012-2014 ($ millions)
Exhibit 42: Daiichi Sankyo: YoY growth rate and revenue of Benicar/Benicar HCT in US 2012-2014 ($ millions)
Exhibit 43: Daiichi Sankyo: YoY growth rate and revenue of AZOR in US 2012-2014 ($ millions)
Exhibit 44: Daiichi Sankyo: YoY growth rate and revenue of TRIBENZOR in US 2012-2014 ($ millions)
Exhibit 45: Daiichi Sankyo: YoY growth rate and revenue of Sevikar in Europe 2012-2014 ($ millions)
Exhibit 46: Daiichi Sankyo: YoY growth rate and revenue of Sevikar HCT in Europe 2012-2014 ($ millions)
Exhibit 47: Daiichi Sankyo: Key takeaways
Exhibit 48: Actelion Pharmaceuticals: YoY growth rate and revenue of Tracleer 2011-2014 ($ billions)
Exhibit 49: Actelion Pharmaceuticals: YoY revenue of Opsumit 2013 and 2014 ($ millions)
Exhibit 50: Actelion Pharmaceuticals: YoY growth rate and revenue of Ventavis 2011-2014 ($ millions)
Exhibit 51: Actelion Pharmaceuticals: YoY growth rate and revenue of Veletri 2011-2014 ($ millions)
Exhibit 52: Actelion Pharmaceuticals: Key takeaways
Exhibit 53: Boehringer Ingelheim: YoY growth rate and revenue of Micardis 2012-2014 ($ millions)
Exhibit 54: Boehringer Ingelheim: Key takeaways
Exhibit 55: Sanofi: YoY growth rate and revenue of Aprovel 2012-2014 ($ millions)
Exhibit 56: Sanofi: YoY growth rate and revenue of Tritace 2012-2014 ($ millions)
Exhibit 57: Sanofi: YoY growth rate and revenue of Lasix 2012-2014 ($ millions)
Exhibit 58: Sanofi: Key takeaways
Exhibit 59: AstraZeneca: Business segmentation by revenue 2015
Exhibit 60: AstraZeneca: YoY growth rate and revenue of Seloken/Toprol 2013-2015 ($ millions)
Exhibit 61: AstraZeneca: YoY growth rate and revenue of Atacand 2013-2015 ($ millions)
Exhibit 62: AstraZeneca: YoY growth rate and revenue of Tenormin 2012-2014 ($ millions)
Exhibit 63: AstraZeneca: Key takeaways


【レポート販売概要】

■ タイトル:高血圧治療薬の世界市場2016-2020
■ 英文:Global Hypertension Drugs Market 2016-2020
■ 発行日:2016年4月13日
■ 調査会社:Technavio
■ 商品コード:IRTNTR9233
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。